Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc (NASDAQ: AMED) provides essential home healthcare, hospice, and high-acuity care services across the United States. This news hub offers investors and industry professionals direct access to verified corporate announcements and financial updates from the home healthcare leader.
Track material developments including quarterly earnings reports, regulatory filings, clinical program expansions, and strategic partnerships. Our curated collection features official press releases, SEC disclosures, and market-moving updates - all organized chronologically for efficient research.
Key content categories include financial performance updates, Medicare/Medicaid compliance changes, care center acquisitions, leadership appointments, and clinical quality initiatives. Bookmark this page for real-time access to operational milestones that shape AMED's position in the $300B home healthcare market.
For stakeholders monitoring the shift toward value-based care models, this resource simplifies tracking of Amedisys' evolving service offerings and regulatory compliance status. Visit regularly to stay informed about critical developments affecting one of America's largest home health providers.
Amedisys, a prominent provider of home health and hospice services, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 p.m. ET. CEO Paul B. Kusserow will represent the company during this event, which is pivotal for stakeholders and investors. Interested parties can access the live webcast of Amedisys’ presentation by visiting their investor relations website. Amedisys specializes in personalized care services across various healthcare settings and serves over 445,000 patients annually.
Amedisys, Inc. (NASDAQ: AMED) has been recognized as one of the top home health and hospice companies by Computerworld in its 2023 Best Places to Work in IT ranking, placing 34th among large organizations. This accolade highlights Amedisys's commitment to employee engagement through excellent compensation, training, and technology access. The rankings are determined through a comprehensive survey of IT professionals and company offerings, underscoring the company’s dedication to creating a supportive work environment for its IT staff.
Amedisys has finalized a joint venture with the University of Arkansas for Medical Sciences (UAMS) to enhance home health services in Searcy and Little Rock, Arkansas. This collaboration offers a range of clinical services under the UAMS Health Comprehensive Care at Home program, including Recovery, Rehabilitation, and Palliative Care. Amedisys now operates 353 care centers across 35 states with approximately 70,000 patients daily. The company's commitment to quality is reflected in its 4.44 QPC Star score and recognition as a top workplace in healthcare.
Amedisys, a provider of home health, hospice, and personal care, announced that CEO Paul B. Kusserow and COO Scott Ginn will present at the Bank of America Securities Home Care Conference on December 6, 2022, at 9 a.m. ET. The presentation will be available via live webcast on the company's investor relations website.
Amedisys, founded in 1982 and headquartered in Baton Rouge, LA, delivers care to over 445,000 patients annually, with approximately 21,000 employees and 547 care centers across 36 states.
Amedisys, Inc. (NASDAQ: AMED) has appointed Scott Ginn as Acting Chief Operating Officer, effective immediately. Ginn, who has been with the company since 2007, will retain his role as Chief Financial Officer while overseeing home health, hospice, and personal care operations. Chairman and CEO Paul Kusserow expressed confidence in Ginn's leadership to deliver strong results. Amedisys is a leading provider of home healthcare services, catering to over 445,000 patients annually across 36 states, showcasing its commitment to high-quality care.
Amedisys, Inc. (NASDAQ: AMED) announced a leadership change on November 17, 2022, with CEO Chris Gerard departing and Paul Kusserow, Chair of the Board, stepping in as interim CEO. The company confirmed its full-year guidance, indicating it is on track to meet previously released targets. Amedisys provides various healthcare services at home, partnering with over 3,000 hospitals and 90,000 physicians, serving more than 445,000 patients annually.
Amedisys (NASDAQ: AMED) announced on November 17, 2022, that President and CEO Chris Gerard has left the company. Paul Kusserow, former CEO, will take over as Chairman and CEO until a new leader is selected. The board expressed confidence in Kusserow's ability to drive profitable growth and innovation. The company is initiating an executive search for Gerard's replacement. Amedisys is a leading home healthcare provider, servicing over 445,000 patients annually with approximately 21,000 employees across 36 states.
Amedisys, Inc. (NASDAQ: AMED) responded to the CY 2023 Home Health Final Rule released by CMS, stating it is an improvement over prior proposals. The rule includes a 4.0% market basket update, the highest for home health agencies, and reduces behavioral adjustment cuts by half. Amedisys acknowledges the support from Congress and advocates in the healthcare community while expressing ongoing concerns about the CMS's budget neutrality methodology. The company remains committed to working with stakeholders to ensure sustainable Medicare payment policies for home health services.
Amedisys, Inc. (NASDAQ: AMED) reported Q3 2022 financial results with a net service revenue increase to $558 million, but net income dropped to $25.6 million from $45 million in Q3 2021. Adjusted EBITDA also fell to $61.5 million. Year-to-date results showed a revenue rise to $1.66 billion, yet net income decreased to $86.9 million compared to $175 million in 2021. The company anticipates adjusted net service revenue between $2.224 billion and $2.230 billion for 2022. Amedisys is focused on partnerships to drive growth despite facing operational challenges.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
